Supplementary Table 1 from SAR131675, a Potent and Selective VEGFR-3–TK Inhibitor with Antilymphangiogenic, Antitumoral, and Antimetastatic Activities
Antoine Alam(Sanofi (France)), Françoise Bono(OSE Immunotherapeutics (France)), Geneviève Gueguen‐Dorbes(Sanofi (France)), Florence Gaujarengues(Sanofi (France)), Jacques Bonnin, Isabelle Blanc, Paul Schaeffer(Universidad La Salle), Marie-Claude Laplace(Sanofi (France)), Pierre Savi(Sanofi (France)), Jean-Pascal Hérault(Sanofi (France)), Pauline Barron(Sanofi (France)), Frédérique Dol(Sanofi (France)), Olivier Duclos(Sanofi (France))
Cited by 0
Related Papers
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
|Nature Medicine|2001|1.7k
PGC-1α Deficiency Causes Multi-System Energy Metabolic Derangements: Muscle Dysfunction, Abnormal Weight Control and Hepatic Steatosis
|PLoS Biology|2005|943
Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells
|JCI Insight|2017|444
PGC-1α Coactivates PDK4 Gene Expression via the Orphan Nuclear Receptor ERRα: a Mechanism for Transcriptional Control of Muscle Glucose Metabolism
|Molecular and Cellular Biology|2005|355